Publications by authors named "Nicholas Shand"

Claim this Profile
I
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
Chiaki Tanaka, Terence O'Reilly, John M Kovarik, Nicholas Shand, Katharine Hazell

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard Burris, Ian Judson, Nicholas Shand

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
Anne O'Donnell, Sandrine Faivre, Howard A Burris, Daniel Rea, Vassiliki Papadimitrakopoulou, Nicholas Shand

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis